Pharmacological Effects of Secondary Bile Acid Microparticles in Diabetic Murine Model

Author(s): Armin Mooranian, Nassim Zamani, Bozica Kovacevic, Corina Mihaela Ionescu, Giuseppe Luna, Momir Mikov, Svetlana Goločorbin-Kon, Goran Stojanovic, Sanja Kojic, Hani Al-Salami*

Journal Name: Current Diabetes Reviews

Volume 18 , Issue 1 , 2022


Article ID: e062620183199
Become EABM
Become Reviewer
Call for Editor

Abstract:

Aim: Examine bile acids effects in Type 2 diabetes.

Background: In recent studies, the bile acid ursodeoxycholic acid (UDCA) has shown potent antiinflammatory effects in obese patients while in type 2 diabetics (T2D) levels of the pro-inflammatory bile acid lithocholic acid were increased, and levels of the anti-inflammatory bile acid chenodeoxycholic acid were decreased, in plasma.

Objective: Hence, this study aimed to examine applications of novel UDCA microparticles in diabetes.

Methods: Diabetic balb/c adult mice were divided into three equal groups and gavaged daily with either empty microcapsules, free UDCA, or microencapsulated UDCA over two weeks. Their blood, tissues, urine, and faeces were collected for blood glucose, inflammation, and bile acid analyses. UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid modulation was not directly linked to diabetes treatment.

Results: UDCA resulted in modulatory effects on bile acids profile without antidiabetic effects suggesting that bile acid modulation was not directly linked to diabetes treatment.

Conclusion: Bile acids modulated the bile profile without affecting blood glucose levels.

Keywords: Lithocholic acid, metabolites, bile acid profile, diabetes, type 2 diabetes mellitus, nanocapsules.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 18
ISSUE: 1
Year: 2022
Published on: 26 June, 2020
Article ID: e062620183199
Pages: 10
DOI: 10.2174/1573399816666200626213735
Price: $95

Article Metrics

PDF: 320